Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Topical Diltiazem Hydrochloride 2% Cream in Subjects With Anal Fissure

NCT01690221 is registered in ClinicalTrials.gov with Ventrus Biosciences, Inc as lead sponsor.

NCT NCT01690221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01690221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Topical Diltiazem Hydrochloride 2% Cream in Subjects With Anal Fissure
Lead sponsor
Ventrus Biosciences, Inc
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2012
Completion date
January 31, 2014
Enrollment
434 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

chronic anal fissures